Search

A study was conducted to examine the effects of cluster size on the extra-atomic relaxation and core-level binding energy (BE) shifts at silicon/silicon oxide interfaces. Results indicated that there are two separate thickness ranges wherein different physical mechanisms cause the thickness-dependent BE shift. Moreover, explicitly accounting for extra-atomic relaxation effects is important when assigning the BE shift of a Si 2p core level to a structural moiety.

The observed binding energy shift for silicon oxide films grown on crystalline silicon changes as a function of film thickness. The physical basis of the shift was previously attributed to a variety of initial state effects (Si-O ring size, stoichiometry, crystallinity and strain), final state effects and extrinsic effects. Through the construction of a structurally homogeneous silicon oxide film on silicon, initial state effects were minimized and the magnitude of final state stabilization was directly measured as a function of film thickness.

The reflection-absorption infrared spectroscopy (RAIRS) is used to observe Si-H bonds within the model, ultrathin silicon oxide. The results show that HSiO3 entities are stable to heat within this model oxide and the reversible, isotopic substitution reactions can be directly observed by RAIRS upon exposure to hydrogen and deuterium atoms.

The interaction of H8Si8O12 with an evaporated gold surface in ultrahigh vacuum represents a simple method for generating approximately 6 angstrom-thick hydrophobic silicon oxide film on gold. Surface binding is thought to comprise of a silicon vertex of the cage chemisorbed to a gold surface atom. The reaction apparently occurs via addition of a Si-H bond followed by reductive elimination of H2. A new and surprising aspect of this chemistry is Si-H activation by the gold surface at 20 degrees C.

Background and Purpose: The benefit of endovascular treatment (EVT) for large vessel occlusion in clinical practice in developing countries like China needs to be confirmed. The aim of the study was to determine whether the benefit of EVT for acute ischemic stroke in randomized trials could be generalized to clinical practice in Chinese population., Methods: We conducted a prospective registry of EVT at 111 centers in China. Patients with acute ischemic stroke caused by imaging-confirmed intracranial large vessel occlusion and receiving EVT were included. The primary outcome was functional independence at 90 days defined as a modified Rankin Scale score of 0 to 2. Outcomes of specific subgroups in the anterior circulation were reported and logistic regression was performed to predict the primary outcome., Results: Among the 1793 enrolled patients, 1396 (77.9%) had anterior circulation large vessel occlusion (median age, 66 [56-73] years) and 397 (22.1%) had posterior circulation large vessel occlusion (median age, 64 [55-72] years). Functional independence at 90 days was reached in 45% and 44% in anterior and posterior circulation groups, respectively. For anterior circulation population, underlying intracranial atherosclerotic disease was identified in 29% of patients, with higher functional independence at 90 days (52% versus 44%; P =0.0122) than patients without intracranial atherosclerotic disease. In the anterior circulation population, after adjusting for baseline characteristics, procedure details, and early outcomes, the independent predictors for functional independence at 90 days were age <66 years (odds ratio [OR], 1.733 [95% CI, 1.213-2.476]), time from onset to puncture >6 hours (OR, 1.536 [95% CI, 1.065-2.216]), local anesthesia (OR, 2.194 [95% CI, 1.325-3.633]), final modified Thrombolysis in Cerebral Infarction 2b/3 (OR, 2.052 [95% CI, 1.085-3.878]), puncture-to-reperfusion time ≤1.5 hours (OR, 1.628 [95% CI, 1.098-2.413]), and National Institutes of Health Stroke Scale score 24 hours after the procedure <11 (OR, 9.126 [95% CI, 6.222-13.385])., Conclusions: Despite distinct characteristics in the Chinese population, favorable outcome of EVT can be achieved in clinical practice in China. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03370939.